Rolling coverage of the latest economic and financial news
Shares in Novo Nordisk have jumped 7.5% this morning after it won approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally.
Yesterday, US regulators gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.
Continue reading...